Avidity Biosciences [RNA] vs Madrigal [MDGL] Detailed Stock Comparison
Avidity Biosciences
NASDAQ
Loading...
Madrigal
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Avidity Biosciences wins in 6 metrics, Madrigal wins in 11 metrics, with 0 ties. Madrigal appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Avidity Biosciences | Madrigal | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -15.34 | -17.67 | Madrigal |
| Price-to-Book Ratio | 4.50 | 12.12 | Avidity Biosciences |
| Debt-to-Equity Ratio | 0.43 | 17.81 | Avidity Biosciences |
| PEG Ratio | -0.18 | 0.24 | Avidity Biosciences |
| EV/EBITDA | -8.76 | -25.25 | Madrigal |
| Profit Margin (TTM) | 0.00% | -54.68% | Avidity Biosciences |
| Operating Margin (TTM) | -4,448.71% | -22.18% | Madrigal |
| Return on Equity | -37.76% | -36.30% | Madrigal |
| Return on Assets (TTM) | -24.01% | -18.31% | Madrigal |
| Free Cash Flow (TTM) | $-307.94M | $-462.03M | Avidity Biosciences |
| 1-Year Return | 2.62% | 61.07% | Madrigal |
| Price-to-Sales Ratio (TTM) | 533.37 | 16.41 | Madrigal |
| Enterprise Value | $4.54B | $7.79B | Madrigal |
| EV/Revenue Ratio | 423.57 | 15.10 | Madrigal |
| Gross Profit Margin (TTM) | N/A | 95.74% | N/A |
| Revenue per Share (TTM) | $0 | $23 | Madrigal |
| Earnings per Share (Diluted) | $-3.56 | $-12.64 | Avidity Biosciences |
| Beta (Stock Volatility) | 0.95 | -1.03 | Madrigal |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Avidity Biosciences vs Madrigal Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Avidity Biosciences | 3.82% | -3.06% | 31.28% | 45.85% | 43.51% | 43.23% |
| Madrigal | 1.99% | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Avidity Biosciences | 2.62% | 103.56% | 56.59% | 56.70% | 56.70% | 56.70% |
| Madrigal | 61.07% | 481.06% | 281.74% | 464.62% | 295.62% | 18.08% |
Performance & Financial Health Analysis: Avidity Biosciences vs Madrigal
| Metric | RNA | MDGL |
|---|---|---|
| Market Information | ||
| Market Cap | $5.72B | $8.46B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 4,696,850 | 451,780 |
| 90 Day Avg. Volume | 3,567,293 | 438,397 |
| Last Close | $46.37 | $415.18 |
| 52 Week Range | $21.51 - $56.00 | $200.63 - $419.99 |
| % from 52W High | -17.21% | -1.15% |
| All-Time High | $56.00 (Nov 11, 2024) | $419.99 (Aug 22, 2025) |
| % from All-Time High | -17.20% | -1.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.88% | 13.54% |
| Quarterly Earnings Growth | 0.88% | 13.54% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | -0.55% |
| Operating Margin (TTM) | -44.49% | -0.22% |
| Return on Equity (TTM) | -0.38% | -0.36% |
| Debt to Equity (MRQ) | 0.43 | 17.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $9.88 | $31.32 |
| Cash per Share (MRQ) | $9.20 | $35.76 |
| Operating Cash Flow (TTM) | $-489,980,992 | $-307,412,992 |
| Levered Free Cash Flow (TTM) | $-259,114,752 | $-219,782,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Avidity Biosciences vs Madrigal
| Metric | RNA | MDGL |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -15.34 | -17.67 |
| Forward P/E | -14.68 | -27.19 |
| PEG Ratio | -0.18 | 0.24 |
| Price to Sales (TTM) | 533.37 | 16.41 |
| Price to Book (MRQ) | 4.50 | 12.12 |
| Market Capitalization | ||
| Market Capitalization | $5.72B | $8.46B |
| Enterprise Value | $4.54B | $7.79B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 423.57 | 15.10 |
| Enterprise to EBITDA | -8.76 | -25.25 |
| Risk & Other Metrics | ||
| Beta | 0.95 | -1.03 |
| Book Value per Share (MRQ) | $9.88 | $31.32 |
Financial Statements Comparison: Avidity Biosciences vs Madrigal
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | RNA | MDGL |
|---|---|---|
| Revenue/Sales | $3.85M | $137.25M |
| Cost of Goods Sold | N/A | $4.51M |
| Gross Profit | N/A | $132.74M |
| Research & Development | $138.13M | $44.17M |
| Operating Income (EBIT) | $-171.14M | $-79.31M |
| EBITDA | $-170.33M | $-69.56M |
| Pre-Tax Income | $-157.32M | $-73.24M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-157.32M | $-73.24M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | RNA | MDGL |
|---|---|---|
| Cash & Equivalents | $254.20M | $183.65M |
| Total Current Assets | $1.43B | $987.98M |
| Total Current Liabilities | $84.87M | $167.24M |
| Long-Term Debt | $2.09M | $118.76M |
| Total Shareholders Equity | $1.33B | $710.64M |
| Retained Earnings | $-1.01B | $-1.88B |
| Property, Plant & Equipment | $19.63M | $4.01M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | RNA | MDGL |
|---|---|---|
| Operating Cash Flow | $-114.30M | $-81.76M |
| Capital Expenditures | $-3.75M | $0 |
| Free Cash Flow | $-128.58M | $-88.89M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | RNA | MDGL |
|---|---|---|
| Shares Short | 16.21M | 3.98M |
| Short Ratio | 6.27 | 11.26 |
| Short % of Float | 0.13% | 0.21% |
| Average Daily Volume (10 Day) | 4,696,850 | 451,780 |
| Average Daily Volume (90 Day) | 3,567,293 | 438,397 |
| Shares Outstanding | 119.89M | 22.00M |
| Float Shares | 98.07M | 11.01M |
| % Held by Insiders | 0.05% | 0.08% |
| % Held by Institutions | 1.08% | 1.07% |
Dividend Analysis & Yield Comparison: Avidity Biosciences vs Madrigal
| Metric | RNA | MDGL |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |